Related Experiment Video

Updated: Jul 13, 2026

Selective Depletion of Microglia from Cerebellar Granule Cell Cultures Using L-leucine Methyl Ester
08:10

Selective Depletion of Microglia from Cerebellar Granule Cell Cultures Using L-leucine Methyl Ester

Published on: July 7, 2015

Maintenance treatment of glutaryl-CoA dehydrogenase deficiency

C Mühlhausen1, G F Hoffmann, K A Strauss

  • 1Departments of Paediatrics, Metabolic Service, University Medical Centers Hamburg, D-20246 Hamburg, Germany.

Journal of Inherited Metabolic Disease
|October 27, 2004
PubMed

Insights

Treatment guidelines for glutaryl-CoA dehydrogenase (GCDH) deficiency are lacking. Further research is needed to understand the disease and document treatment outcomes effectively.

Area of Science:

  • Biochemistry
  • Genetics
  • Metabolic Disorders

Background:

  • Glutaryl-CoA dehydrogenase (GCDH) deficiency is a rare inherited metabolic disorder.
  • Current treatment strategies for GCDH deficiency lack international consensus.
  • Pathophysiology and clinical progression of GCDH deficiency remain incompletely understood.

Purpose of the Study:

  • To summarize existing knowledge and workshop findings on GCDH deficiency treatment.
  • To identify challenges hindering the development of international treatment recommendations.
  • To highlight the need for standardized documentation and prospective studies.

Main Methods:

  • Review of published literature on GCDH deficiency.
  • Consensus discussion at the 3rd International Workshop on Glutaryl-CoA Dehydrogenase Deficiency (Heidelberg, Germany, October 2003).
  • Analysis of factors limiting treatment guideline development.

Main Results:

  • No established international treatment recommendations for GCDH deficiency currently exist.
  • Key barriers include limited understanding of disease pathophysiology.
  • Lack of prospective studies and objective clinical outcome documentation (e.g., video) impede progress.

Conclusions:

  • Development of international treatment guidelines for GCDH deficiency is urgently needed.
  • Further research is required to elucidate disease mechanisms.
  • Prospective studies with standardized outcome measures are essential for advancing patient care.

More Related Videos

In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease10:16

In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease

Published on: December 20, 2017

Assessment of Glutamine as a Fuel Source for Alveolar Macrophages Exposed to Chronic Ethanol Using an Extracellular Flux Bioanalyzer08:37

Assessment of Glutamine as a Fuel Source for Alveolar Macrophages Exposed to Chronic Ethanol Using an Extracellular Flux Bioanalyzer

Published on: November 15, 2024

Related Concept Videos

Urea Cycle01:23

Urea Cycle

The urea cycle describes how liver cells convert ammonia to urea. Ammonia is a toxic waste product of protein catabolism. Land animals must convert ammonia into the less toxic urea which can be safely eliminated by the kidneys through urine. Marine animals excrete ammonia directly, and the surrounding water dilutes the ammonia to safe levels.
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic sinusitis...
Phase II Reactions: Glutathione Conjugation and Mercapturic Acid Formation01:22

Phase II Reactions: Glutathione Conjugation and Mercapturic Acid Formation

Glutathione, a tripeptide made up of glutamate, cysteine, and glycine, is a critical player in the detoxification of drugs and xenobiotics via a process known as glutathione conjugation or mercapturic acid formation. This phase II biotransformation reaction involves the covalent binding of glutathione to a drug or its metabolite, enhancing the compound's water solubility and enabling its excretion.
Several distinctive characteristics distinguish glutathione conjugation from other phase II...
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
Jaundice01:25

Jaundice

Jaundice, or icterus, is the yellow discoloration of the skin, sclerae, and mucous membranes. It happens when plasma bilirubin levels rise above 2.5-3 mg/dL, leading to bilirubin deposition in tissue.Bilirubin is a byproduct of hemoglobin degradation. In macrophages, hemoglobin breaks down into globin and heme. Globin is converted into amino acids, while heme is turned into biliverdin by heme oxygenase, which is then reduced to unconjugated bilirubin by biliverdin reductase.Unconjugated...